Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.
Archive | Melanoma News
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma
Posted in Melanoma News, Health Professionals, Video Reports
Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors
Melanoma is the third most common cancer in the adolescent and young adult (AYA) population, however no studies have addressed the occurrence of adverse health conditions following melanoma treatment in these survivors.
Posted in Melanoma News, Publications, Scientific Publications
Discovering new bait for the immune system may lead to additional treatments for melanoma. Congratulations Andreas Behren, Katherine Woods, Jonathan Cebon, Stephen Wong and colleagues
A collaborative study, led by ONJCRI and the Monash Biomedicine Discovery Institute (BDI) at Monash University, has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.
Posted in Melanoma News, MRV Research, MRV Publications
Albury Wodonga Regional Cancer Centre fundraising drive seeks 100 bearded ambassadors
Terry Greaves was feeling fit and healthy until the start of this year, when he was diagnosed with metastatic melanoma.
Posted in Melanoma News, Patients, Latest News
